Sultana Shamima, Morishita Shoji, Awai Kazuo, Kawanaka Koichi, Ohyama Yoichi, Nakayama Yoshiharu, Imuta Masanori, Arakawa Akihiko, Yamashita Yasuyuki
Department of Diagnostic Radiology, Kumamoto University Postgraduate School, Japan.
Radiat Med. 2003 Nov-Dec;21(6):239-45.
To compare enhancement of the aorta, portal vein, liver, and tumor with contrast medium of a higher iodine concentration to that with one of a standard iodine concentration for liver dynamic CT within the same patient with known liver cirrhosis and hepatocellular carcinoma (HCC).
Fifty-three patients with known cirrhosis and HCC underwent repeat computed tomographic (CT) examinations within three months, the first with either 300 (n=26) or 370 mgI/ml (n=27) of nonionic contrast material. In the second examination, only concentration was altered. In 28 patients, weight was equal to or more than 65 kg, and in 25 patients it was less than 65 kg. The CT numbers (HU) of the aorta, portal vein, liver, and tumor were obtained, and CT attenuation was compared between the two concentration studies. The degree of enhancement was scored qualitatively.
Mean enhancement values of the aorta, liver, portal vein, and tumor were greater with the 370 mgI/ml injections than with the 300 mgI/ml injections throughout the study. In visual analysis, the difference in aortic, portal venous, liver, and tumor enhancement was not statistically significant between the two groups in patients weighing less than 65 kg. However, in patients weighing 65 kg or more, strong aortic and portal venous enhancement (rated as good or excellent) occurred more frequently with the 370 mgI/ml injections than with the 300 mgI/ml injections.
Higher contrast enhancement was achieved in patients who received 370 mgI/ml of contrast material, resulting in better tissue contrast between liver parenchyma and HCCs. However, this difference was not visually significant in patients weighing less than 65 kg.
在已知患有肝硬化和肝细胞癌(HCC)的同一患者中,比较使用高碘浓度对比剂与标准碘浓度对比剂进行肝脏动态CT扫描时主动脉、门静脉、肝脏和肿瘤的强化情况。
53例已知患有肝硬化和HCC的患者在三个月内接受了重复计算机断层扫描(CT)检查,第一次使用300(n = 26)或370 mgI/ml(n = 27)的非离子型对比剂。在第二次检查中,仅改变对比剂浓度。28例患者体重等于或超过65 kg,25例患者体重小于65 kg。获取主动脉、门静脉、肝脏和肿瘤的CT值(HU),并比较两种浓度研究之间的CT衰减情况。对强化程度进行定性评分。
在整个研究过程中,注射370 mgI/ml对比剂时主动脉、肝脏、门静脉和肿瘤的平均强化值均高于注射300 mgI/ml对比剂时。在视觉分析中,体重小于65 kg的患者两组之间主动脉、门静脉、肝脏和肿瘤强化的差异无统计学意义。然而,在体重65 kg或以上的患者中,注射370 mgI/ml对比剂时主动脉和门静脉的强烈强化(评为良好或优秀)比注射300 mgI/ml对比剂时更频繁出现。
接受370 mgI/ml对比剂的患者实现了更高的对比增强,从而在肝实质和HCC之间产生了更好的组织对比。然而,这种差异在体重小于65 kg的患者中在视觉上并不显著。